Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVM NASDAQ:CYCC NASDAQ:IRD NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$10.49-6.7%$6.99$1.98▼$39.30$72.19M0.54372,145 shs223,440 shsCYCCCyclacel Pharmaceuticals$7.12-4.6%$8.27$3.08▼$597.60$15.95M0.15705,624 shs80,828 shsIRDOpus Genetics$1.27-0.8%$1.13$0.65▼$1.75$76.09M0.07524,107 shs130,163 shsSTROSutro Biopharma$1.06+3.9%$0.82$0.52▼$4.80$89.86M1.571.22 million shs1.09 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI-4.99%+20.73%+25.73%+372.27%-65.15%CYCCCyclacel Pharmaceuticals-2.86%-4.60%-9.14%+34.41%-97.07%IRDOpus Genetics0.00%+7.56%+15.32%+23.08%+127,999,900.00%STROSutro Biopharma+0.99%+13.92%+25.46%+20.28%-76.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$10.49-6.7%$6.99$1.98▼$39.30$72.19M0.54372,145 shs223,440 shsCYCCCyclacel Pharmaceuticals$7.12-4.6%$8.27$3.08▼$597.60$15.95M0.15705,624 shs80,828 shsIRDOpus Genetics$1.27-0.8%$1.13$0.65▼$1.75$76.09M0.07524,107 shs130,163 shsSTROSutro Biopharma$1.06+3.9%$0.82$0.52▼$4.80$89.86M1.571.22 million shs1.09 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI-4.99%+20.73%+25.73%+372.27%-65.15%CYCCCyclacel Pharmaceuticals-2.86%-4.60%-9.14%+34.41%-97.07%IRDOpus Genetics0.00%+7.56%+15.32%+23.08%+127,999,900.00%STROSutro Biopharma+0.99%+13.92%+25.46%+20.28%-76.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/ACYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AIRDOpus Genetics 3.00Buy$7.33477.43% UpsideSTROSutro Biopharma 2.14Hold$4.47321.38% UpsideCurrent Analyst Ratings BreakdownLatest CYCC, IRD, STRO, and CVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025STROSutro BiopharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $3.006/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/ACYCCCyclacel Pharmaceuticals$40K398.72N/AN/A($58.87) per share-0.12IRDOpus Genetics$10.99M6.92N/AN/A$0.21 per share6.05STROSutro Biopharma$62.04M1.45N/AN/A$0.54 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/ACYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-723.64%-145.51%11/10/2025 (Estimated)IRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%11/11/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.53N/AN/AN/A-201.32%-852.70%-58.67%11/12/2025 (Estimated)Latest CYCC, IRD, STRO, and CVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/7/2025Q2 2025STROSutro Biopharma-$0.39-$0.14+$0.25-$0.14$14.55 million$63.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09CYCCCyclacel PharmaceuticalsN/A5.775.77IRDOpus Genetics0.061.901.90STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%CYCCCyclacel Pharmaceuticals23.58%IRDOpus Genetics14.97%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%CYCCCyclacel Pharmaceuticals51.20%IRDOpus Genetics6.60%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI436.88 million64.67 millionOptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionableIRDOpus Genetics1459.91 million55.95 millionN/ASTROSutro Biopharma24084.77 million81.72 millionOptionableCYCC, IRD, STRO, and CVM HeadlinesRecent News About These CompaniesRA Capital Management L.P. Takes Position in Sutro Biopharma, Inc. $STROSeptember 4 at 7:02 AM | marketbeat.comVaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3 at 7:50 AM | quiverquant.comQSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesSeptember 1, 2025 | marketbeat.comVelan Capital Investment Management LP Boosts Holdings in Sutro Biopharma, Inc. $STROAugust 31, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Hold" from AnalystsAugust 30, 2025 | americanbankingnews.comAffinity Asset Advisors LLC Makes New Investment in Sutro Biopharma, Inc. $STROAugust 28, 2025 | marketbeat.comWall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to SellAugust 25, 2025 | marketbeat.comSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comWells Fargo & Company Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $3.00August 13, 2025 | marketbeat.comSutro Biopharma price target lowered to $3 from $4 at Wells FargoAugust 12, 2025 | msn.comSutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street ZenAugust 10, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)August 9, 2025 | theglobeandmail.comSutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 8, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comSutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 7, 2025 | globenewswire.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from AnalystsAugust 5, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug ConjugatesJuly 24, 2025 | finanznachrichten.deHere's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash WiselyJuly 23, 2025 | finance.yahoo.comSutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug ConjugatesJuly 23, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCatalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025If Qualcomm Holds $145, Its Next Move Could Be MassiveBy Sam Quirke | August 12, 2025CYCC, IRD, STRO, and CVM Company DescriptionsCEL-SCI NYSE:CVM$10.49 -0.75 (-6.67%) Closing price 04:00 PM EasternExtended Trading$10.63 +0.14 (+1.33%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Cyclacel Pharmaceuticals NASDAQ:CYCC$7.12 -0.34 (-4.56%) Closing price 04:00 PM EasternExtended Trading$6.98 -0.14 (-1.91%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Opus Genetics NASDAQ:IRD$1.27 -0.01 (-0.78%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.01 (+0.79%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Sutro Biopharma NASDAQ:STRO$1.06 +0.04 (+3.92%) Closing price 04:00 PM EasternExtended Trading$1.11 +0.05 (+4.72%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Lockheed Martin: Is the Market Overlooking This Defensive Giant? Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
